Category: Regenerative Treatments

PRP is not one product. Platelet dose, leukocyte profile, red cell contamination, and pre-activation change what reaches the joint, and what the studies show.

In a 2026 survey of 357 orthopaedic patients, 66.9% believed orthobiologics could treat cartilage injuries. How we decide when an injection does not fit.

A data review before the session, a 60-minute physician-led root-cause discussion, and a written terrain roadmap naming the bottlenecks and the sequence.

PRP results for tennis elbow depend on when you measure and who was enrolled. The trial-by-trial eligibility and exclusion criteria, stated plainly.

In a MOST analysis of 395 knees, 66% of bone marrow lesions changed size over 30 months and half resolved. How to read the finding on your report.

Level I evidence supports PRP in rotator cuff tears and discourages it in Achilles and patellar tears. Why the injection target decides what the data mean.

Why there is no single recovery schedule after PRP, BMAC or Lipogems, what the phases actually are, and the survey data on what patients wrongly expect.

A staged return-to-lifting plan after PRP, BMAC or Lipogems: readiness checks, three loading stages, knee and disc modifications, and the signs that mean stop.

SI joint pain drives 15-25% of back pain, yet only 45% of fusion patients had a diagnostic injection first. Why confirmation comes before PRP or BMAC.

Heel pain that did not respond to first-line care: where PRP, BMAC and Lipogems actually sit in the published treatment sequence, and what has to be confirmed first.